netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Chapter Links...
 Details...
03.01.01.01  Expand sub section  Selective Beta2 agonists
03.01.01.01  Expand sub section  Short-acting beta2 agonists
Salbutamol
(100 micrograms/dose CFC free Metered Dose Inhaler (MDI))
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Brands include Ventolin Evohaler«, Airomir« inhaler.
 
Salbutamol
(100 microgram/dose, 200microgram per dose)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Dry powder inhaler (DPI)(Easyhaler«)
Breath-actuated inhaler (Airomir« Autohaler, Salamol Easi-breathe«)
Dry powder inhaler(Ventolin«Accuhaler) 
   
Terbutaline
(500 micrograms/dose)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Dry powder inhaler (DPI)(Bricanyl« Turbohaler) 
   
Salbutamol
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Inhalers (see separate entries)
Nebuliser solution
Tablets
Oral solution
Injection
Solution for infusion


Restricted ItemáThe use of short-acting adrenoreceptor agonists for tocolyis in premature labour has been restricted to 48 hours maximum parenteral use under specialist supervision, after a European safety review (MHRA 2013 - see Drug Safety Update)  
Link  MHRA Drug Safety Update Nov 2013
   
Terbutaline
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Inhaler (see separate entry)
Nebuliser solution 5mg/2ml (Respules«
   
03.01.01.01  Expand sub section  Long-acting beta2 agonists
 note  In the management of asthma, long-acting beta 2 agonists (LABAs) should always be prescribed with concomitant inhaled corticosteroid (ICS) and only when ICS alone is not sufficient to control asthma symptoms. Review LABA therapy regularly, prescribe the lowest effective dose, and stop if there is no benefit.
Formoterol
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Dry powder inhaler 12 micrograms/dose (Easyhaler«)
Dry powder inhaler 6 micrograms/dose, 12 micrograms/dose (Oxis« Turbohaler)

 
Salmeterol
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Metered dose inhaler 25 micrograms/dose (Serevent Evohaler«)
Dry powder inhaler (Serevent Accuhaler«)

 
   
Indacaterol
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Dry powder inhaler 150 microgram/dose, 300 microgram/dose (Onbrez Breezhaler«)

May be considered as a treatment option for COPD patients in whom another long acting β-adrenoceptor agonist (LABA) would be suitable (GMMMG).

Not licensed for asthma.  
   
 ....
 Non Formulary Items
Bambuterol  (Bambec«)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Fenoterol

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Formoterol Fumarate  (Atimos« Modulite)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
 
Formoterol Fumarate  (Foradil®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary